{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:05:23Z","timestamp":1791273923224,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.coph.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T15:59:53Z","timestamp":1412006393000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?"],"prefix":"10.1016","volume":"18","author":[{"given":"Malcolm GP","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.coph.2014.09.008_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coph.2014.09.008_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.41.3.563","article-title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated Ampc \u03b2-lactamase, and the loss of an outer membrane protein","volume":"41","author":"Bradford","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1086\/661597","article-title":"Outcomes and genetic relatedness of carbapenem-resistant Enterobacteriaceae at Detroit medical center","volume":"32","author":"Marchaim","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.coph.2014.09.008_bib0020","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/cid\/cis543","article-title":"Carbapenem-resistant Enterobacteriaceae: an emerging problem in children","volume":"55","author":"Logan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2014.09.008_bib0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3109\/10428194.2012.723210","article-title":"Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies","volume":"54","author":"Satlin","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coph.2014.09.008_sbref0030","series-title":"Antibiotic Resistance Threats in the United States","author":"Centers for Disease Control Prevention","year":"2013"},{"key":"10.1016\/j.coph.2014.09.008_bib0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ajic.2011.10.013","article-title":"\u2018Swimming in resistance\u2019: co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa","volume":"40","author":"Marchaim","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.coph.2014.09.008_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"39","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2014.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2014.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10\u00d7\u201920 progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2014.09.008_bib0055","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CMR.00033-13","article-title":"Investigational antimicrobial agents of 2013","volume":"26","author":"Pucci","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2014.09.008_bib0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ja.2013.86","article-title":"Antibiotics in the clinical pipeline in 2013","volume":"66","author":"Butler","year":"2013","journal-title":"J Antibiotics"},{"key":"10.1016\/j.coph.2014.09.008_sbref0065","first-page":"147","article-title":"Cautious optimism for the antibacterial pipeline","volume":"9","author":"Pucci","year":"2014","journal-title":"Microbe"},{"key":"10.1016\/j.coph.2014.09.008_bib0070","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.01374-09","article-title":"In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone","volume":"54","author":"Morrow","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0075","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01197-09","article-title":"Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates","volume":"54","author":"Lauderdale","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0080","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0085","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0090","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1128\/AAC.02374-12","article-title":"Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii","volume":"57","author":"Higuchi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0095","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"EV-035: novel 2-pyridone based topoisomerase inhibitors with broad-spectrum activity against MDR pathogens, including quinolone resistance","author":"Heim","year":"2012"},{"key":"10.1016\/j.coph.2014.09.008_bib0100","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"EV-035: potent antibiotic series against biothreat agent Burkholderia pseudomallei","author":"Goldman","year":"2012"},{"key":"10.1016\/j.coph.2014.09.008_bib0105","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bmcl.2012.11.073","article-title":"Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part II: development of inhibitors with broad spectrum, gram-negative antibacterial activity","volume":"23","author":"Trzoss","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2014.09.008_sbref0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents","author":"Tari","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2014.09.008_bib0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Exp Rev Antiinfect Ther"},{"key":"10.1016\/j.coph.2014.09.008_bib0120","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0130","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.2011.06323.x","article-title":"Antibiotics in development targeting protein synthesis","volume":"1","author":"Sutcliffe","year":"2011","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.coph.2014.09.008_bib0140","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0145","series-title":"24th ECCMID","article-title":"Poster P0299. In vitro potency of novel, fully synthetic tetracyclines against MDR gram-negative pathogens including carbapenem-resistant Enterobacteriaceae","author":"Xiao","year":"2014"},{"key":"10.1016\/j.coph.2014.09.008_bib0150","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0155","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jac\/dks009","article-title":"In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii","volume":"67","author":"Higgins","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0160","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/jac\/dks527","article-title":"Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant gram-negative bacilli","volume":"68","author":"Hofer","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0165","series-title":"2-Substituted Cephem Compounds","author":"Liao","year":"2014"},{"key":"10.1016\/j.coph.2014.09.008_bib0170","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Mechanism-based cephalosporin inhibitors of metallo- and serine-carbapenemases","author":"Sutton","year":"2013"},{"key":"10.1016\/j.coph.2014.09.008_bib0175","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2011.02.004","article-title":"In vitro activity of CXA-101 plus tazobactam (cxa-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"70","author":"Titelman","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.coph.2014.09.008_bib0185","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States (USA) and European (EU) hospitals (2012)","author":"Sader","year":"2013"},{"key":"10.1016\/j.coph.2014.09.008_sbref0190","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2014.09.008_bib0195","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime\u2013avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0200","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.02436-12","article-title":"Antimicrobial activity of ceftaroline\u2013avibactam tested against clinical isolates collected from U.S. Medical centers in 2010\u20132011","volume":"57","author":"Sader","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0205","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam\u2013avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0210","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"21","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0215","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkt118","article-title":"Activity of biapenem (RPX2003) combined with the boronate \u03b2-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2014.09.008_bib0220","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Design, synthesis and structure activity relationship of novel substituted amides containing diazabicyclic heterocyclic compounds as broad-spectrum \u03b2-lactamase inhibitors","author":"Maiti","year":"2013"},{"key":"10.1016\/j.coph.2014.09.008_bib0225","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cbic.201200276","article-title":"Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics","volume":"13","author":"Werneburg","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.coph.2014.09.008_bib0230","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1182749","article-title":"Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa","volume":"327","author":"Srinivas","year":"2010","journal-title":"Science"},{"issue":"Suppl. 4","key":"10.1016\/j.coph.2014.09.008_bib0235","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1093\/cid\/cir051","article-title":"Rapid diagnostics and appropriate antibiotic use","volume":"52","author":"Rice","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2014.09.008_sbref0240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrmicro3245","article-title":"ND4BB: addressing the antimicrobial resistance crisis","volume":"12","author":"Rex","year":"2014","journal-title":"Nat Rev Microbiol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489214001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489214001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T11:35:12Z","timestamp":1565868912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489214001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":48,"alternative-id":["S1471489214001076"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2014.09.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}